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Abstract
Background
During pulmonary tuberculosis (PTB) antibodies are generated to trehalose esters of myco-
lic acids which are cell wall lipids of Mycobacterium tuberculosis (Mtb). Attempts have been
made to use these complex natural mixtures in serological tests for PTB diagnosis.
Aim
The aim of this work was to determine whether a serological test based on a panel of defined
individual trehalose esters of characteristic synthetic mycolic acids has improved diagnostic
accuracy in distinguishing patients with culture positive PTB from individuals who were Mtb
culture negative.
Method
One hundred serum samples from well-characterized patients with presumptive tuberculo-
sis, and diagnosed as having pulmonary smear and culture positive TB, or being culture and
smear negative were evaluated by ELISA using different combinations of synthetic antigens
and secondary antibodies. Using cut-off values determined from these samples, we vali-
dated this study blind in samples from a further 249 presumptive TB patients.
Results
With the first 100 samples, detailed responses depended both on the precise structure of
the antigen and on the secondary antibody. Using a single antigen, a sensitivity/specificity
combination for smear and culture positive PTB detection of 85 and 88% respectively was
achieved; this increased to 96% and 95% respectively by a statistical combination of the
results with seven antigens. In the blind study a sensitivity/specificity of 87% and 83% was
reached with a single antigen. With some synthetic antigens, the responses from all 349
samples were significantly better than those with the natural mixture. Combining the results
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for seven antigens allowed a distinction between culture positive and negative with a ROC
AUC of 0.95.
Conclusion
We have identified promising antigen candidates for serological assays that could be used
to diagnose PTB and which could be the basis of a much-needed, simple, rapid diagnostic
test that would bring care closer to communities.
Introduction
Despite advances in the development of diagnostics for pulmonary tuberculosis (PTB), poor
case-detection rates remain an obstacle to its control in many low and middle-income countries.
Access to any kind of current diagnostic service remains a problem for significant sections of
society [1]. Even when accessible, smear microscopy (still the most commonly used PTB diagnos-
tic) has a poor sensitivity and about half the PTB cases that are tested may be a false negative. The
newer molecular diagnostic tests for PTB are much more sensitive but, due to the infrastructure
required for the equipment, the test facility tends to be centralised and becomes even less accessi-
ble to the poorer and more marginalized; their performance remains under review [2]. New tests
are needed to allow rapid diagnosis closer to affected communities [3,4], the ideal being a robust,
simple serological test that could dramatically improve PTB detection. Such a test has proved elu-
sive. The complexity and variability of the antigenic make-up of Mycobacterium tuberculosis
(Mtb), of the host immunological response to the organism and the chronic, fluid nature of Mtb,
infection and disease all present challenges [5]. An additional challenge has been the lack of well-
defined Mtb antigens in sufficient quantities. Either large quantities of poorly defined or unde-
fined mixed antigens, or very small quantities of well-defined extracted antigens, were available.
These inadequacies in antigen resources have compromised the development of reproducible
assays, and hampered our ability to understand the immunology of infection and disease.
Recently, it has been shown that B cells are functionally altered through the course of tuber-
culosis (TB), opening new challenges to our understanding on their role in TB pathogenesis
[6]. There have been extensive reviews of serodiagnostic assays for TB [7–11]. The World
Health Organisation (WHO) has recently summarised a large number of such assays; it indi-
cated that none of these reach the standards of specificity and sensitivity required [12], but
identified a clear requirement for a fast and robust serodiagnostic test for point of care use that
does reach the required standards. It has defined the target product profile for such an assay
[13]. Various studies, e.g. [14–16], have described heterogeneity in responses during infection
and disease, and indeed temporal differences in the nature of the responses through the course
of infection/disease. A successful serological assay for the diagnosis of TB is likely to be based
on a matrix of reactions to a panel of key antigens [17], perhaps differentiated on the basis of
the immunoglobulin class involved.
Several antigens have been examined and numerous analyses of serodiagnostic assays have
been produced [18–26]. The use of natural lipid antigens extracted from Mtb cells in serodiag-
nosis has been reported, primarily by two groups. These antigens, present in the cells of myco-
bacteria and some related organisms, contain long chain ‘mycolic acids’ (MA) (1), which are
generally either bound to the cell wall as esters or as, eg., non-wall-bound trehalose dimyco-
lates (2) (TDM, ‘cord factor’) and monomycolates (TMM) (3) (Fig 1A) [27–29]. They are pres-
ent as complex mixtures of different carbon chain lengths as well as different structural sub-
classes (mainly α-, methoxy and keto- in Mtb) that can form a fingerprint of a particular
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Fig 1. (a) A general mycolic acid structure (1), together with TDM (2) and TMM (3); (b) Synthetic MA
components of TDM and TMM studied in this work; (c) Mixed TDM studied in this work. Abbreviations: Y, the
proximal group, is normally either a cis-cyclopropane, a trans-cyclopropane with a methyl substituent on the adjacent
carbon distal from the hydroxy-acid, a cis-alkene, or a trans-alkene with a methyl substituent on the adjacent carbon
proximal to the hydroxy-acid. X, the distal substituent, is normally a cis-cyclopropane (α-MAs), a -CH(CH3)CH(OCH3)-
group (methoxy-MAs) or a–CHCH3CO- group (keto-MAs).
https://doi.org/10.1371/journal.pone.0181414.g001
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Mycobacterium. The first diagnostic method, using as antigens complex mixtures of TDM (2),
isolated from Mtb, by ELISA has been reported by Yano [30–41]. The highest average response
was for smear-positive PTB patients, followed by atypical mycobacteriosis and then by the
smear-negative PTB patients. Serum from healthy controls and cancer patients did not gener-
ate responses, leading to an overall sensitivity of 84% and specificity of 100% [30]. The results
using IgM as the secondary antibody were less clear. In those treated for PTB, the response
declined during treatment, reaching the level of controls after 3 years [32]. Despite excellent
reported sensitivity and specificity, obtained primarily using samples from Japan, the method
was among those not supported for use by the WHO [12]. The second method, reported by
Verschoor uses complex mixtures of free MAs (1) derived by hydrolysis of the mycolate esters
present in the cells [42–46]. In this case, the accuracy in ELISA is rather lower [47], but signifi-
cantly improved by using a more complex biosensor system [43–46]. Nonetheless, one advan-
tage of both this and the Yano method is that the antigen-antibody interactions are retained in
TB/HIV co-infected patients [31]. The detailed composition of the complex mixtures of indi-
vidual lipids, MAs (1) and their TDMs (2) and TMMs (3) (Fig 1A), changes during the pro-
gression of disease and with the virulence of the mycobacterial strain [48–50]. Moreover,
similar, but characteristic, mixtures of MAs are present in other mycobacteria, including com-
mon environmental mycobacteria, and in a number of related organisms such as Rhodococcus
[51,52]. One hypothesis for the failure of these two methods to reach the required standards of
accuracy is that serum from patients without TB may be cross-reacting with Mtb antigens as a
result of patients’ previous exposure to mycobacteria other than Mtb, or that the antibodies
present at the disease stage at which the serum was taken do not match the antigen mixture
used for diagnosis. A further complication may be that overall antibody levels change during
disease progression or that responses to antibodies to lipids are heterogeneous [53,54]. Many
people, though infected with Mtb, do not develop TB disease and are said to have latent TB
infection (LTBI). It may be that some antibodies to lipids are generated during LTBI, and this
leads to false positives in diagnosing TB disease [55].
Natural TDMs from different classes of MA show differential responses in assays for TB
[36]. Given the effect of the balance of these classes, and of stereochemistry within the classes,
on disease profile [48–50], one possibility for increasing the accuracy of such assays is to use a
diagnostic device based on a set of highly defined antigens, single synthetic sugar esters of MA
matching individual components of either Mtb or of other mycobacteria [56–59].
This paper describes an evaluation of these synthetic lipid antigens as diagnostic markers
for smear and culture positive PTB in comparison with TDM extracted from Mtb cells and, for
comparison, bovine TDM (the latter was included to determine whether there were any signif-
icant differences in response caused by a different balance in the complex mixtures of MA and
TDM between human and bovine samples). It explores the heterogeneity of immunological
responses to these antigens among people with presumptive TB [60] in disease-endemic coun-
tries; it identifies patterns of Ag/Ig class reactions associated with confirmed pulmonary TB;
and it evaluates the use of such patterns to predict confirmed PTB in a set of well-characterized
blinded specimens. It seeks to determine whether combining the results of a set of such assays
with different antigens can improve diagnostic performance to a level which, when applied on
an appropriate platform, might meet the requirements set for a point of care assay [12,13].
Materials and methods
Study design
TDR TB Specimen Bank provided serum specimens that had been collected with all the neces-
sary ethical approval and patient consent for distribution to diagnostic test developers [61].
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Patients had presented at healthcare facilities in different countries with symptoms suggestive
of pulmonary TB (PTB). In this study, those having PTB were positive on culture, and those
not having PTB were negative on culture.
Within the study format given in Fig 2, these samples were divided into 3 sub-sets. The clin-
ical characteristics of the first two sets of 50 serum samples (n = 100) are given in Tables 1 and
2. These samples were used to develop the assay and were not tested blind. Having developed
the assay using these sets, we validated it through blinded testing of a further 249 samples pro-
vided from TDR without any accompanying data (Table 3). The results were analysed using
cut-off values set for the first 100 samples. WHO/TDR only un-blinded the analysis once
results had been reported to them. The results from all 349 samples were considered together
in order, where data were available, to analyse the various sub-groups, such as previous TB,
positive TST, BCG vaccination, other active diseases, and country effects (S3 File). However it
should be noted that data on TST, BCG and other diseases were not complete and not collected
in a standardised way across sites due to differences in practices between countries and to lim-
ited capacity for the diagnosis of other diseases in many of the countries.
The serum samples
The TDR TB Specimen Bank [61] samples were collected from 349 patients with respiratory
symptoms suggestive of PTB in 10 countries. No specific treatment had been started in any of
the patients enrolled. Detailed information was available on the patient profile, the country of
origin, and the symptoms, as well as the microbiology on solid and/or liquid culture, and, in
some cases of follow-up observations. Clinical data also included chest X-ray, where available.
Of the 349 patients, 102 had culture positive PTB. Of these 100 were also smear positive (Fig 2;
Tables 1–3). The 247 patients who were considered not to have PTB were all culture negative.
Four of these patients gave weakly positive smears but nevertheless were considered not to
have PTB on the basis of negative cultures. All culture negative patients were followed up for
two months and found still to be negative. Eleven of the negatives were given treatment and
three improved, five showed no change, one was worse and for two there was no follow up.
Investigations included repeat cultures if the respiratory symptoms had persisted. Approxi-
mately twice as many negative specimens as positive specimens were provided, because of the
development and early validation aims of the study.
The assay
ELISA were carried out on 96-well flat-bottomed polystyrene micro-plates by slight modifica-
tion of methods reported earlier [31, 45]. Antigens were dissolved in hexane to give a concen-
tration 15 μg/ml. 50 μl of this solution was added to each well, and the solvent was left to
evaporate at room temperature. Control wells were coated with hexane (50 μl/well) only.
Blocking was achieved by adding 400 μl of 0.5% casein/PBS buffer (pH 7.4) to each well, and
the plates were incubated at 25˚C for 30 minutes. The buffer was aspirated and any excess was
flicked-out until the plates were dry. Serum (1 in 20 dilution in casein/PBS buffer, unless other-
wise stated) (50 μl/well) was added and incubated at 25˚C for 1 hour. The plates were washed
with 400 μl casein/PBS buffer 3 times using an automatic washer, and any excess buffer was
flicked out onto a paper towel until dry. Secondary antibody (all peroxidase conjugated; pro-
duced in goat, diluted in casein/PBS buffer, 50 μl/well) [from Sigma Aldrich UK: A0170 (Anti-
Human IgG (Fc specific),1:2000); A8667 (Anti-Human IgG (whole molecule), 1:1000); A6029
(Anti-Human IgG (γ-chain specific), 1:2000); A6907 (Anti-Human IgM (μ-chain specific),
1:333); A0295 (Anti-Human IgA (α-chain specific), 1:1667] was added, and incubated at 25˚C
for 30 minutes. The plates were again washed 3 times with 400 μl casein/PBS buffer using an
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automatic washer, and any excess buffer was again flicked out. OPD substrate (50 μl / well)
(o-phenylenediamine (1 mg/ml) and H2O2 (0.8 mg/ml) in 100 mM citrate buffer) was then
Fig 2. Study format. Abbreviations: TB: tuberculosis; BCG: Bacillus Calmette–Gue´rin; TST: tuberculin skin test; u/k:
unknown.
https://doi.org/10.1371/journal.pone.0181414.g002
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Table 1. Demographic and clinical characteristics of the first 50 patients whose sera were evaluated.
TB No TB
Culture positive Culture negative Total p value
N. 10 N. 40 N. 50
Age median (IQR) 28.5 (23–40) 40 (25–54) 38.0 (24–50.5) .0183
Sex, MALE N (%) 7 (70%) 22 (55) 29 (58) 0.389
AFB smear score/total (%) Score 0: 0 Score 0: 38 (95) Score 0/ 38 (76) <0.001
Score 1: 4(40) Score 1: 2 (5) Score 1/ 6 (12)
Score 2: 3(30) Score 2/ 3 (6)
Score 3: 3(30) Score 3/ 3(6)
Solid and/or liquid culture positive 10 (100) 0 10 (20) NA
BCG vaccination recorded N (%) 7 (70) 22 (55) 29 (58) 0.380
Previous TB reported N (%) 1 (10) 6 (15) 7 (14) 0.504
Other diseases N (%) 2 (20) 7 (17.5) 9 (18)
Site: Pulmonary 8 (80) 40 (100) 48 (96) 0.178
Extra-pulmonary/pulmonary 1 (10) 0 1 (2)
Unknown 1 (10) 0 1 (2)
Region of Origin N (%) Asia 5 (50) Asia 13 (32.5) Asia 18 (36) <0.001
Africa 5 (50) Africa 7 (17.5) Africa 12 (24)
S. America 20 (50) S. America 20 (40)
https://doi.org/10.1371/journal.pone.0181414.t001
Table 2. Demographic and clinical characteristics of the second 50 patients whose sera were evaluated.
TB No TB
Culture positive Culture negative Total p value
N. 17 N. 33 N. 50
Age median (IQR) 35 (25.5–43.5) 41 (33–49.5) 38 (28.5–46.5) 0.233
Sex, MALE N (%) 10 (59) 14 (42) 24 (48) 0.189
AFB smear score/total (%) Score 0: 0 Score 0: 32 (97) Score 0: 32 (64) <0.001
Score 1: 3 (18), Score 1: 1(3), Score 1: 4 (8),
Score 2: 10 (59) Score 2: 10 (20),
Score 3: 4 (23) Score 3: 4 (8)
Solid and/or liquid culture positive 17(100) 0 17 (34) NA
BCG vaccination recorded N (%) 9 (53) 18 (54.5) 27 (54) 0.953
2 unknown 4 unknown 6 unknown
Previous TB reported N (%) 1 (6) 8 (24) 9 (18) 0.171
Other diseases N (%) 5 (17.5) 18 (54.5) 23 (46)
Site: Pulmonary 16 (94) 33 (100) 49 (98)
Unknown 1
TST Positive 3 (17.5) 7 (21) 10 (20)
Negative 2 (11.8) 7 (21) 9 (18)
Not done 12 19
Region of origin Africa (8) Africa (9) Africa (17) <0.001
S. America (2) S. America (13) S. America (15)
Asia (6) Asia (0) Asia (6)
W.Europe (1) W. Europe (6) W. Europe (7)
N. America (5) N. America (5)
Footnotes: TST: tuberculin skin test
https://doi.org/10.1371/journal.pone.0181414.t002
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added, and the plates were incubated for a further 30 minutes at 25˚C. The colour reaction was
terminated by adding 2.5 M H2SO4 (50 μl/well), and the absorbance was read at 492 nm. Each
measurement was carried out in quadruplicate and an average was taken.
The results presented are the un-modified absorbance figures recorded at 492 nm and, do
not have the absorbance at 630 nm, or the blank for a plate with no serum subtracted (S1 File).
The antigens
Natural human and bovine TDM were purchased from Sigma-Aldrich UK. Synthetic antigens
were prepared as previously described [56–59]. Their structures are given in Fig 1B/1C and
Table 4.
Statistical methods
Statistical testing of the sample demographics was carried out using the coin package in R
using an exact Wilcoxon-Mann-Whitney test for continuous data and a Chi-Squared test
based on a Monte Carlo resampled distribution for the contingency data [62]. For the data
analysis based on multiple antigen response and disease status, a training set was formed from
the first two data sets (in total 100 samples, with 27 smear and culture positive PTB cases). Val-
idation was done from the third data set in which the disease status was blind at the time of
classification. Classification of PTB status based on assay response levels was estimated using
tree based Random Forest and Generalised Boosted Model (GBM) classifiers [63,64], trained
Table 3. Demographic and clinical characteristics of the third set of patients: Validation study performed on 249 samples.
TB No TB
Culture positive Culture negative Total p value
N. 75 N. 174
Age median (IQR) 29 (25–43) 47 (29–63) 37.5 (26–57.8) <0.001
Sex, MALE N (%) 48 (64) 81 (46.5) 129 (52) <0.001
AFB smear score/total (%) Score 0: 2 (3) Score 0: 173 (99) Score 0: 175 (70) <0.001
Score 1: 18 (24) Score 1: 1(1) Score 1: 19 (7.5)
Score 2: 17 (22.5) Score 2: 17 (7)
Score 3: 38 (50.5) Score 3: 38 (15)
Solid and or liquid culture positive 75(100) 0 (0) 75 (30.1) <0.001
BCG vaccination recorded N (%) 21 (28) 60 (34.5) 81 (32.5) 0.001
Unknown 4 36
Previous TB reported N (%) 13 (17) 35 (20) 48 (19) 0.552
Other diseases N (%) 26 (35) 113 (65) 139 (56)
Site (number, percent) Pulmonary 74 (98.5) 173 (99.5) 247 (99) 0.563
Extra-pulmonary + pulmonary 1 (1.5) 1 (0.5) 2 (1)
TST Positive 6 (8) 45 (26) 51 (20.5) 0.216
Negative 1 (1.5) 42 (24) 43 (17)
Not done 68 87 155
Region of origin Asia (24) Asia (5) Asia (29) <0.001
S. America (21) S. America (52) S. America (73)
N. America (29) N. America (29)
Africa (27) Africa (58) Africa (85)
W. Europe (3) W. Europe (30) W. Europe (33)
Footnotes. TST: tuberculin skin test
https://doi.org/10.1371/journal.pone.0181414.t003
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with the training set in R [65]. An initial screen of the antigens selected those showing a varia-
tion of response across the cases and evidence of discrimination between TB status. From the
training, a subset of 7 of antigens was selected based on variable importance and a new classi-
fier estimated from the training set using only these antigens. Predictions of disease status
were then made for the validation data using this classifier. ROC curves and AUC values were
estimated with the pROC package [66] in R [6]. Significance of pairwise differences between
AUC values was estimated using the DeLong’s test [67] implemented in the pROC R package.
Optimal diagnostic cut-off points were determined using Youden’s J statistic which maximises
sensitivity + specificity.
Results
The experimental ELISA was based on TDMs (structures 2) or TMMs (structures 3) (Fig 1,
Table 4) prepared from single synthetic MAs containing specific combinations of cis- or trans-
cyclopropane and different oxygenated functionality, patterns known to have different effects
on innate immune system responses and to change disease virulence [48–50].
Results for the initial 50 serum samples
Natural human and bovine TDM and a number of synthetic TDMs and TMMs were examined
using a set of 50 serum samples and, in some cases, several different secondary antibodies.
Commercial natural human (n15) and bovine TDM (n20) gave significantly different medians
with smear and culture positive PTB and culture negative sets using IgG (whole) secondary
antibody (p< .001), and AUCs of 0.86 and 0.88 on ROC analysis (Table 5; Fig A in S2 File).
The human TDM gave slightly lower AUCs with IgG(Fc) (0.82) and IgG(gamma) (0.80) sec-
ondary antibodies, though the medians were significantly different (p = 0.001 and 0.003). The
medians for the two sets (Fig B in S2 File) were not significantly different with IgM and IgA
secondary antibody (n18 and n19) (p = 0.616 and 0.050) and the AUCs were lower (0.55 and
0.70) (Table 5).
Most of the single synthetic TDMs and TMMs gave AUC values above 0.8 when IgG or IgG
(Fc) secondary antibody was used. Median responses and differences between medians for
Table 4. Synthetic trehalose dimycolates (TDMs), trehalose monomycolates (TMMs) and model TDMs used.
Derived TDM Derived TMM
Mycolic acid (Fig 1B) Compound number Reference Compound number Reference
A 4 54 5 54
B 6 54 7 54
C 8 55 9 55
D 10 55 11 55
E 12 54 13 54
F 14 54 15 54
G 16 54 17 54
H 18 54 19 54
I 20 54 21 54
J 22 56
CH3(CH2)22COOH 23 55
CH3(CH2)20COOH 24 55
K (Fig 1C) 25 54
https://doi.org/10.1371/journal.pone.0181414.t004
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Table 5. Results of the ELISA with first set of 50 human sera (10 Mtb culture positive PTB and 40 Mtb culture negative patients) using the different
antigen/antibody combinations.
TB No TB
Type of
compound¥¥
Compound
number
Method# 2nd
Ab
used
Smear and
culture
positive
PTB ##
Culture
negative##
p value of the
comparisons of
medians ELISA
results from culture
positive PTB and
culture negative
samples
ROC AUC¥
(95% interval)
Optimum
Cut-off
from ROC
Sensitivity/
Specificity
from optimum
ROC cut-off
Median
Absorbance
(IQR)
Median
Absorbance
(IQR)
Significance
relative to n15
Human
TDM
Natural
mixture
n15 IgG 3.12 (2.83–
3.36)
2.03 (1.3–
2.77)
<0.001 0.86 (0.74–
0.99)
2.79 80/80
Natural
mixture
n16 IgG
(Fc)
2.6 (1.46–2.91) 0.95 (0.63–
1.59)
0.001 0.82 (0.68–
0.95)
1.41 80/68
Natural
mixture
n17 IgG
(g)
2.84 (1.52–
3.24)
1.21 (0.64–
2.04)
0.003 0.80 (0.64–
0.95)
1.96 70/73
Natural
mixture
n18 IgM 2.08 (0.98–2.8) 2.3 (1.15–
2.93)
0.616 0.55* (0.34–
0.76)
1.79 50/63
Natural
mixture
n19 IgA 0.43 (0.29–1) 0.31 (0.2–
0.37)
0.050 0.70 (0.52–
0.89)
0.36 70/73
Bovine TDM Natural
mixture
n20 IgG 3.02 (2.85–
3.24)
1.93 (1.06–
2.39)
<0.001 0.88 (0.77–
0.99)
2.79 90/85
α TDM 4 n21 IgG 2.7 (1.34–3.35) 1.99 (1.45–
2.76)
0.233 0.63** (0.39–
0.86)
2.98 50/85
α TMM 5 n22 IgG 3.11 (2.46–
3.59)
1.91 (1.31–
2.78)
0.001 0.81 (0.67–
0.95)
2.40 80/65
α TDM 6 n23 IgG 3.06 (2.88–3.4) 2.19 (1.22–
2.89)
0.001 0.82 (0.70–
0.94)
2.81 90/68
6 n3 IgG
(Fc)
3.1 (2.29–3.2) 0.96 (0.58–
1.67)
<0.001 0.89 (0.80–
0.99)
1.70 90/78
α TMM 7 n24 IgG 2.94 (2.5–3.29) 1.79 (1.23–
3.06)
0.040 0.71* (0.56–
0.86)
2.18 90/55
7 n4 IgG
(Fc)
2.31 (1.54–
2.84)
1.01 (0.59–
2.15)
0.027 0.73* (0.57–
0.88)
1.44 80/58
MeOTDM 12 n27 IgG 3.17 (2.64–
3.35)
1.73 (1.18–
2.8)
<0.001 0.85 (0.73–
0.97)
2.34 90/68
12 n28 IgG
(Fc)
2.58 (1.97–
2.75)
0.73 (0.49–
1.32)
<0.001 0.89 (0.76–
1.00)
1.78 80/90
12 n29 IgM 3.07 (2.21–
3.14)
2.98 (2.32–
3.2)
0.961 0.50***
(0.30–0.69)
3.05 60/63
12 n30 IgA 1.39 (0.59–
1.93)
0.6 (0.34–
0.79)
0.017 0.74 (0.57–
0.91)
1.19 60/90
MeOTMM 13 n31 IgG 1.68 (1.09–3) 0.81 (0.65–
1.17)
<0.001 0.84 (0.71–
0.97)
1.06 80/70
13 n32 IgG
(Fc)
1.13 (0.65–
3.05)
0.68 (0.5–
1.15)
0.060 0.69 (0.48–
0.90)
1.07 60/73
13 n33 IgM 1.72 (1.3–1.82) 1.52 (1.1–
2.22)
0.982 0.50***
(0.30–0.70)
1.53 70/55
13 n34 IgA 0.51 (0.27–
0.87)
0.27 (0.18–
0.39)
0.0724 0.68 (0.49–
0.88)
0.36 60/73
MeOTDM 14 n35 IgG 3.17 (2.99–
3.44)
1.66 (0.85–
2.82)
<0.001 0.86 (0.75–
0.98)
2.94 80/80
14 n1 IgG
(Fc)
3.48 (2.04–
4.08)
0.76 (0.51–
1.19)
<0.001 0.94 (0.86–
1.00)
1.34 90/83
(Continued )
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smear and culture positive PTB and culture negative samples were much lower and not signifi-
cant for IgM or IgA. This is in line with results when using natural mixtures of TDMs [68, 69].
Individual TDMs and TMMs from each of the common α-, methoxy and keto-classes in
Mtb gave higher specificities than the natural mixtures. Within the classes, high AUCs were
obtained with antigens having a range of different absolute stereochemistries about the differ-
ent functional groups. Even the model compound 23 with no functionality in the α-chain of
the MA (nx01) gave a significant difference between the medians for the two sets. The highest
Table 5. (Continued)
TB No TB
Type of
compound¥¥
Compound
number
Method# 2nd
Ab
used
Smear and
culture
positive
PTB ##
Culture
negative##
p value of the
comparisons of
medians ELISA
results from culture
positive PTB and
culture negative
samples
ROC AUC¥
(95% interval)
Optimum
Cut-off
from ROC
Sensitivity/
Specificity
from optimum
ROC cut-off
Median
Absorbance
(IQR)
Median
Absorbance
(IQR)
Significance
relative to n15
14 n1b IgG
(Fc)
0.88 (0.4–2.98) 0.32 (0.27–
0.41)
<0.001 0.86 (0.73–
0.98)
0.39 80/67
MeOTMM 15 n2 IgG
(Fc)
2.96 (1.83–
3.74)
0.65 (0.47–
1.18)
<0.001 0.92 (0.85–
1.00)
1.32 90/85
t-MeOTDM 16 n47 IgG
(Fc)
1.06 (0.57–
3.01)
0.38 (0.29–
0.49)
<0.001 0.90 (0.81–
1.00)
0.50 90/75
t-MeOTMM 17 n36 IgG 2.68 (2.19–
3.04)
1.13 (0.77–
1.82)
<0.001 0.87 (0.76–
0.98)
1.99 80/78
17 n37 IgG
(Fc)
2.08 (1.2–2.91) 0.58 (0.37–
1.03)
<0.001 0.88 (0.78–
0.99)
1.07 80/78
t-ketoTDM 18 n38 IgG 2.07 (0.79–
3.34)
0.81 (0.5–1.4) 0.026 0.73* (0.52–
0.93)
1.68 60/80
18 n5 IgG
(Fc)
2.79 (1.42–
3.08)
0.91 (0.56–
1.56)
0.001 0.82 (0.69–
0.96)
1.93 70/83
t-ketoTMM 19 n6 IgG
(Fc)
3.09 (2.16–
3.87)
0.97 (0.6–
1.76)
<0.001 0.88 (0.78–
0.99)
1.79 90/77
ketoTDM 20 n39 IgG
(Fc)
3.09 (2.16–
3.87)
0.97 (0.6–
1.76)
<0.001 0.95 (0.89–
1.00)
1.88 90/89
23 nx01 IgG 2.4 (1.35–3.25) 1.12 (0.8–
1.69)
0.002 0.82 (0.68–
0.96)
1.60 70/73
24 nx02 IgG 3.09(2.92–
3.42)
2.79 (2.45–
3.24)
0.057 0.70* (0.54–
0.85)
2.82 100/53
Footnotes:
# Method: combination of a compound and a secondary antibody
## evaluations were done at a serum dilution of 1:20, except n1b and n47 at 1:80. In each case the secondary antibody was peroxidase conjugated and the
binding was measured by addition of o-phenylenediamine and H2O2 in citrate buffer and the colour reaction was terminated by the addition of acid.
¥ ROC analyses are presented in Fig A in S2 File. Standard significance values indicated by stars (* P<0.05, ** P<0.01, *** P<0.001) are for comparisons
of ROC results for each method relative to those for method n15. Significance of pairwise differences between AUC values was estimated using the
DeLong’s test [67] implemented in the pROC R package. Ab: antibody, TDM: trehalose dimycolate, TMM: trehalose monomycolate ROC: receiver operator
characteristics AUC: area under curve PTB: pulmonary tuberculosis IQR: interquartile range.
¥¥ MeOTDM: TDM from cis-cyclopropane containing methoxy-MA. MeOTMM: TMM from cis-cyclopropane methoxy-MA. tMeOTDM: TDM from trans-
cyclopropane methoxy-MA. tMeOTMM: TMM from trans-cyclopropane methoxy-MA. ketoTDM: TDM from cis-cyclopropane ketoMA. t-ketoTDM: TDM from
trans-cyclopropane ketoMA. t-ketoTMM: TMM from trans-cyclopropane ketoMA. α TDM: TDM from α-MA. α TMM: TMM from α-MA.
https://doi.org/10.1371/journal.pone.0181414.t005
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AUC of all (0.95) was obtained with the TDM 17 derived from a cis-cyclopropane containing
keto-MA (n39).
Results for the second 50 serum samples
A second set of 50 serum samples was then examined (Table 6; Figs C and D in S2 File). Some
15 of the antigen/antibody combinations giving good culture positive PTB/culture negative
distinction with the first 50 samples were included in this study, together with an additional
set of antigens covering different structural types of MA. In general, the results with the second
set of samples were in agreement with the first set, though in some cases AUC values were
rather higher (n4, 0.84 compared to 0.73; n32, 0.86 compared to 0.69) or lower (n2, 0.79 com-
pared to 0.92), probably due to the small sample sets. All of the antigen-secondary antibody
combinations again gave a significant difference between smear and culture positive PTB and
culture negative sets (p<0.05) (Table 6). With this set of samples, both commercial natural
Table 7. Combined results of the ELISA with the two sets of 50 sera (27 culture positive PTB and 73 culture negative patients) using selected anti-
gen/antibody combinations.
TB No TB
Antigen or
compound
number
Method# Secondary
antibody
Smear and
culture
positive PTB
Culture
negative
p
value##
ROC AUC (95%
interval)
Optimum
Cut-off from
ROC
Optimum
Sensitivity/
Specificity
combination from
ROC
Cut-off for
100%
sensitivity
SpecificityBased on
this cut-off
Median
absorbance
IQR Median
absorbance
IQR Significance
relative to n15
Human TDM n15 IgG (whole) 3.11 2.92–
3.37
1.72 1.09–
2.7
<0.001 0.88 (0.80–
0.95)
2.88 78/86 >1.81 51
Bovine TDM n20 IgG (whole) 3.1 2.86–
3.34
1.69 1.08–
2.31
<0.001 0.89 (0.83–
0.96)
2.45 89/81 >1.93 58
6 n1 IgG (Fc) 3.14 2.47–
3.58
0.99 0.54–
1.79
<0.001 0.87 (0.80–
0.94)
1.26 89/81 >0.54 38
7 n3 IgG (Fc) 2.9 1.59–
3.41
0.95 0.53–
2.04
<0.001 0.80 (0.71–
0.89)
1.72 89/74 >1.15 59
12 n4 IgG (Fc) 2.78 1.63–
3.21
0.69 0.43–
1.43
<0.001 0.88 (0.80–
0.95)
1.38 85/64 >0.62 38
13 n32 IgG (Fc) 2.71 1.04–
3.14
0.7 0.47–
1.25
<0.001 0.81 (0.71–
0.91)
2.14 59/93 >0.37 12
14 n28 IgG (Fc) 3.25 2.07–
3.55
0.72 0.4–
1.19
<0.001 0.90 (0.83–
0.96)
1.25 89/81 >0.61 44
14 n1b IgG (Fc) 1.1 0.49–
2.45
0.3 0.22–
0.42
<0.001 0.86 (0.76–
0.96)
0.47 79/81 >0.14 1
15 n2 IgG (Fc) 2.84 1.25–
3.37
0.62 0.41–
1.17
<0.001 0.83 (0.73–
0.93)
1.52 70/86 >0.22 3
16 n47 IgG (Fc) 1.51 0.86–
3.27
0.37 0.27–
0.57
<0.001 0.91 (0.86–
0.97)
0.49 96/72 >0.46 62
17 n37 IgG (Fc) 2.97 1.41–
3.21
0.71 0.4–
1.44
<0.001 0.84 (0.77–
0.92)
0.77 100/56 >0.22 49
18 n5 IgG (Fc) 2.99 1.95–
3.4
0.82 0.46–
1.47
<0.001 0.87 (0.79–
0.94)
1.92 78/82 >0.84 53
19 n6 IgG (Fc) 3.24 2.24–
3.78
0.97 0.56–
1.93
<0.001 0.84 (0.75–
0.93)
1.79 85/74 >0.44 14
20 n39 IgG (Fc) 3.25 2.97–
3.66
0.64 0.34–
1.24
<0.001 0.94 (0.89–
0.98)
1.32 100/75 >1.39 77
Footnotes:
# Method: as for Table 5.
## Comparison of medians ELISA results from culture positive PTB and culture negative samples. Abbreviations: PTB: pulmonary tuberculosis; IQR:
interquartile range. Ab: antibody, TDM: trehalose dimycolate, TMM: trehalose monomycolate ROC: receiver operator characteristics AUC: area under curve
TB: tuberculosis
https://doi.org/10.1371/journal.pone.0181414.t007
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human (n15) and bovine TDM (n20) give slightly higher AUCs using IgG secondary antibody
than with the first set, the bovine TDM performing slightly better (AUC 0.90).
A number of additional antigens were also tested with this set (Table 6). Again, all the anti-
gen-secondary antibody combinations responses associated with smear and culture positive
PTB rather than culture negative sets. The ROC AUCs ranged from 0.71 to 0.87 (Fig C in S2
File). Within this set, no method was significantly better than using natural human TDM and
IgG secondary antibody.
Combined results for the first 100 serum samples
The results for a sub-set of antigens for the whole set of the first 100 samples were combined
(Table 7; Fig 3). All antigen-secondary antibody combinations give a significantly higher
response with smear and culture positive PTB than culture negative sets. In agreement with
what was reported above, one of the antigens, 20 (method n39), gives a rather better discrimi-
nation between culture positive PTB and culture negative, with an AUC of 0.94, than the natu-
ral human or bovine mixtures (0.88 and 0.89), and antigen 16 (n47), AUC 0.91, performs
almost as well (Fig E in S2 File).
Analysis of the responses for each individual antigen to each of the sera showed subtle
differences in pattern. The results from seven antigen/secondary antibody combinations
(n15, n20, n3, n28, n32, n1, n39), were therefore combined using a Random Forest classifier
and principal co-ordinate analysis of case proximity, leading to the distribution shown in
Fig 4. The two axes represent different combinations of the results with each of the antigens.
Two clear groups can be identified, one in the top left hand corner for the bulk of smear and
culture positive PTB samples, the other in the top right for culture negative, no TB, samples;
in between was a region containing both sets of samples. Using Generalized Boosted Regres-
sion Models (GBM) statistics to combine the results from the 7 antigen/antibody combina-
tions provided a prediction of culture positive PTB/culture negative to best match the
WHO/TDR diagnosis as a rank order from 0–1, predicting the likelihood that the sample
was culture positive PTB (0 very unlikely, 1 very likely). By setting the value of the cut-off
for a positive assignment at 0.24, a sensitivity of 100% and a specificity of 89% was achieved.
Sensitivity+specificity was maximised with a cut-off of 0.35; the sensitivity was 96% and the
specificity 95% (Table 8). A ROC analysis of these combined data gave an AUC of 0.98 (Fig
F in S2 File).
To set-up a cut-off for the “blind-study” we used the optimal combination of sensitivity and
specificity provided by a ROC analysis for the first 100. In addition we evaluated the sensitivity
and specificity produced by setting the minimum cut-off for each antigen to provide 100% sen-
sitivity for these samples (Table 7).
A blind study of 249 serum samples
Having established that the synthetic antigens do provide responses in ELISA that match well
with the diagnosis of smear and culture positive PTB, and that the results from more than one
antigen could be combined to enhance the sensitivity and specificity, the method was applied
in a blind study of an additional 249 serum samples from presumptive TB patients from the
TDR TB Specimen Bank (Table 9; Fig 5, Fig G in S2 File). Patients were enrolled as specified in
the Material and Methods section. Note that in a number of cases, the patients are recorded as
having either a history of previous TB, and/or of Bacillus Calmette–Gue´rin (BCG) vaccination,
and/or having been affected by a recent or current co-infection (e.g. malaria).
Using cut-off values set prior to the blind study, the sensitivity, specificity and ROC AUC
for the natural mixtures of human TDM were 64%, 84% and 0.80 and for the bovine TDM
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were 73%, 79%, and 0.84 respectively. Three of the synthetic antigens performed better, anti-
gen 20 (n39) giving a sensitivity of 83%, a specificity of 84%, and an AUC of 0.90. For compari-
son, with the GBM classifier set at the cut-off to achieve 100% sensitivity based on the 100
Fig 3. The distribution of responses (absorbances) from the first 100 serum samples from patients with culture positive PTB or culture
negative (no TB). Each method n15—n39 is described in Table 7. The bars indicate the medians. In each case the secondary antibody was peroxidase
conjugated and the binding was measured by addition of o-phenylenediamine and H2O2 in citrate buffer and the colour reaction was terminated by the
addition of acid. Each individual measurement was carried out in quadruplicate. The bars indicate the medians.
https://doi.org/10.1371/journal.pone.0181414.g003
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sample training, a sensitivity of 81%, specificity of 86% and an AUC of 0.83 resulted, while set-
ting a cut-off to achieve maximum sensitivity+specificity gave values of 74%, 87% and 0.81
repectively.
Fig 4. Proximity of individual cases using a Random Forest classifier [63] trained with the absobance for the antigens n15, n20, n3, n28, n32,
n1, n39 for the 100 sample data set in R [64]. Proximities were reduced to 2-dimensions using multidimensional scaling. Dimensions 1 and 2 can
be interpreted as weighted statistical combinations of the absorbances for each serum sample with the antigens. Abbreviations: as for Fig 3.
https://doi.org/10.1371/journal.pone.0181414.g004
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The results for the complete set of 349 sera
Having determined the results for the 249 samples in the above blind study, the data for all 349
samples were then combined (Fig 6, Fig H in S2 File). All the synthetic MA sugar ester-second-
ary antibody combinations showed a significant difference between smear and culture positive
PTB and culture negative sets (p<0.001), with AUCs of 0.84–0.91 (Table 10); in comparison,
the free MA H (Fig 1B) gave much lower median absorbances and an AUC of just 0.57.
A statistical combination of the results from all the antigen-antibody combinations (except
for n44), using a Random Forest classifier, led to a principal co-ordinate analysis that allowed
a distinction between culture positive PTB and culture negative (Fig 7) with a ROC AUC of
0.95. For this set of samples 100 of the 102 culture positive PTB samples were both smear and
culture positive. Two were smear negative, culture positive; both identified as positives in the
above assays.
A more detailed analysis of the individual results showed that, with the cut-off values set by
ROC analysis of the initial 100 samples (Table 7), 73 of the 102 samples diagnosed as samples
from culture positive PTB patients, were above the cut-off for all antigens used (except method
n44) and a further 12 were above the cut-off for six of the seven antigens.
An analysis of the effect of country of origin and other sub-groups is presented in S3 File,
but must be considered with caution due to lack of standardisation and quality assurance in
data collection.
Discussion
We set-up a serological test for the diagnosis of TB. Using ELISA with two initial sets of 50
serum samples from patients with presumptive TB [60], we showed that a number of combina-
tions of a defined single synthetic trehalose di- and mono-mycolate antigen and a secondary
antibody gave a better distinction than complex natural mixtures of TDM between patients
who were diagnosed with smear and culture positive PTB, and those who were negative in cul-
ture. The sensitivity and specificity, and the pattern of responses, in each case depended on the
detailed structure of the antigen and on the secondary antibody used. By combining the results
from a set of individual antigens using GBM statistics, the distinction could be increased to
provide a sensitivity and specificity of 100% and 89% respectively and a ROC AUC of 0.98,
meeting the criteria of the WHO target product profile [13].
Table 8. Predictive value of a statistical combination of the responses for methods n15, n20, n3, n28,
n32, n1, n39 using the initial 100 samples with GBM statistics.
Cut off used for culture positive PTB using GBM output >0.24 >0.35
Sensitivity (%) 100 96
Specificity (%) 89 95
True positive 27 26
False positive 8 4
True negative 65 69
False negative 0 1
Total 100 100
PPV 77 87
NPV 100 99
Footnotes: A ROC analysis of the numerical predictions (in range 0 (culture negative) to 1 (smear and
culture positive PTB)) for each serum sample combined using GBM statistics gave an AUC of 0.98 (see Fig
F in S2 File). NPV: negative predictive value. PPV: positive predictive value.
https://doi.org/10.1371/journal.pone.0181414.t008
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In these initial studies with some 38 combinations of synthetic trehalose ester and second-
ary antibody, 14 with the complete set of 100 samples, TDMs and TMMs derived from the
common classes of MA in Mtb (α-, keto- and methoxy-MA), all gave ROC AUCs above 0.85
using IgG or IgG(Fc) secondary antibodies. Among the antigens evaluated, two gave a better
discrimination between smear and culture positive PTB and culture negative sets, with AUCs
of 0.94 and 0.91, than natural human mixture (0.88).
To validate these results, an additional 249 samples were run blind, using cut-off values set
studying the initial 100 samples. An optimal sensitivity and specificity combination of 88%
and 83% for a single synthetic antigen/secondary antibody combination (n5) was obtained; a
number of the synthetic antigen/secondary antibody combinations gave a better distinction
than natural TDM. In contrast, the free MA H (Fig 1B) (method n44) showed a ROC value of
just 0.57.
All of the patients whose sera were included in this study presented with presumptive TB
[60] and the majority presented at health facilities in countries with high burdens of TB. They
Table 9. Results of the blind analysis of the ELISA for 249 sera (75 culture positive PTB and 174 culture negative patients) using selected combina-
tions of compounds and antibodies.
TB No TB
Antigen or
compound
number
Method# Secondary
antibody
Culture
positive
PTB$
Culture
negative
P## ROC
AUC¥
(95%
interval)
Sensitivity/
Specificity from
optimum cut-off
from ROC on
first 100 samples
Cut-off based
on first 100
samples to
give 100%
sensitivity
Sensitivity/
Specificity
with that cut-
off
Median IQR Median IQR
Human TDM n15 IgG 3.17 2.48–
3.43
1.46 0.91–
2.46
<0.001 0.80
(0.75–
0.86)
64/84 >1.81 83/61
Bovine TDM n20 IgG 3.18 2.41–
3.43
1.29 0.79–
2.17
<0.001 0.84
(0.79–
0.89)
73/79 >1.93 80/71
6 n3 IgG (Fc) 3.55 2.25–
4.0
0.84 0.51–
1.47
<0.001 0.87***
(0.83–
0.92)
81/79 >1.15 92/70
12 n28 IgG (Fc) 3.09 1.86–
3.51
0.73 0.42–
1.45
<0.001 0.83
(0.77–
0.89)
80/72 >0.61 91/40
13 n32 IgG (Fc) 2.83 1.3–
3.35
0.69 0.41–
1.22
<0.001 0.83
(0.77–
0.89)
65/87 >0.37 95/22
14 n1 IgG (Fc) 3.21 2.14–
3.72
0.65 0.43–
1.25
<0.001 0.88***
(0.84–
0.93)
84/75 >0.54 96/37
20 n39 IgG (Fc) 3.43 2.07–
4.0
0.51 0.32–
0.92
<0.001 0.90***
(0.86–
0.95)
83/84 >1.39 83/85
Footnotes:
# Method: as for Table 5.
$ 73 of 75 were also smear positive
## Comparison of medians from culture positive PTB and culture negative samples. The serum dilution used was 1:20.
¥ROC analyses for these samples after unblinding are presented in Fig G in S2 File. Standard significance values indicated by stars (* P<0.05, ** P<0.01,
*** P<0.001) are for comparisons of ROC results for each method relative to those for method n15. Significance of pairwise differences between AUC
values was estimated using the DeLong’s test [67] implemented in the pROC R package. Abbreviations: PTB: pulmonary tuberculosis. IQR: interquartile
range. Ab: antibody, TDM: trehalose dimycolate, TMM: trehalose monomycolate ROC: receiver operator characteristics AUC: area under curve.
https://doi.org/10.1371/journal.pone.0181414.t009
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were thus representative of populations in which a rapid TB diagnostic would be deployed.
Combining the results for all 349 samples, we show that an ELISA based on the responses of
Fig 5. The distribution of responses (absorbances), with medians, in the ELISA assay with the third set of 249 samples using 7 different
antigens, natural TDM from MTB (n15), natural bovine TDM (n20) and five synthetic antigens the medians for which are presented in Table 9.
The assay was run blind and then un-blinded for analysis compared to cut-off values set for the first 100 samples as in Table 7. Method: as for Fig 3.
Abbreviations: TDM: trehalose dimycolate.
https://doi.org/10.1371/journal.pone.0181414.g005
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serum antibodies to trehalose esters of single synthetic MA, using IgG(Fc) secondary antibody,
was more accurate for TB diagnosis than similar assays using natural mixtures of TDMs.
Moreover, the combination of the results obtained using more than one antigen with the
full set of 349 samples again further improved the accuracy of the assay. By using principal co-
ordinate analysis, the combination of the results from 7 antigens led to a 2D-plot in which the
Fig 6. ELISA responses (absorbances) and medians of smear and culture positive PTB and culture negative sets for all 349 samples
using 8 different antigens, natural TDM from MTB (n15), natural bovine TDM (n20) and six synthetic antigens with secondary
antibodies as described in Table 9. The ROC analysis is given in Fig H in S2 File. Method: as for Fig 3. Abbreviations: TDM: trehalose
dimycolate. Mtb: Mycobacterium tuberculosis.
https://doi.org/10.1371/journal.pone.0181414.g006
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results for serum samples from smear and culture positive PTB/culture negative (no TB)
patients clearly appeared in different areas, with a number in the region between these
Fig 7. Proximity of individual cases using a Random Forest classifier [59] trained with the absorbances with the 349 serum samples for the
antigens n15, n20, n3, n28, n32, n1, n39. The ROC AUC for this analysis based on the principal co-ordinate (x-axis) compared to PTB or no PTB
diagnosis was 0.95. AUC: area under curve.
https://doi.org/10.1371/journal.pone.0181414.g007
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extremes. This effect of using a set of antigens is in contrast to recent reports of the use of a
multiple set of protein antigens, where little improvement was observed [70]. The reason for
this is not yet clear, but may reflect increased structural diversity of binding sites between the
different lipid antigens compared to protein antigens.
Among the samples tested, no serological response to any antigen was found in 7 samples
that were culture positive, bringing the performance of the assay below the optimum WHO
target product profile [13]. A number of factors, separately or collectively, could account for
these very low responses relative to the culture negative set. Thus, the samples came from a
banked set and some may have degraded in storage and use, the disease at the time the
serum sample was taken may not have progressed to antibody production, levels of antibod-
ies to lipids may fluctuate during active disease as antibodies to protein antigens are known
to do [14–16,53], or there may be differences in response from one country or region or
from one population to another. Differences may also be affected by Mtb lineage and strain.
Moreover, it is known that antibody responses in patients with TB can be heterogeneous
[53]. A very low serological response in some TB patients has been shown in studies using
natural TDM [28], and the responses have been associated with the time of clinical onset of
symptoms [29].
Co-infection with HIV is reported not to interfere with serodiagnostic TB assays using
either natural TDM [30–41] or natural MA mixtures [42–45]. Although the TDR TB Speci-
men Bank contains sera from HIV-positive patients with symptoms suggestive of PTB, no
such sera were included in this initial study; a further study to evaluate the assay with
defined synthetic antigens in TB/HIV co-infected serum is on-going. Further work is also
required to optimise the combination of synthetic MA based antigens, for example to
include the more challenging smear negative samples and to remove the chance of false pos-
itives from other mycobacterial infections [71], as well as applying it in a rapid, reliable and
robust testing format.
In conclusion, within the set of 349 serum samples selected from different countries, an
assay based on the antibody detection against selected individual sugar esters of synthetic MAs
had a higher accuracy to distinguish smear and culture positive PTB from smear and culture
negative patients, than did the complex natural mixture of natural TDMs, and gave responses
that depended on the specific structure of the antigen. By combining the results from more
than one synthetic antigen, e.g, including different structural classes of MA, the performance
of the assay could be further improved. This is in contrast to some multiplex assays using pro-
tein antigens [70,72], perhaps reflecting differences in antibody-lipid interactions from anti-
body-protein interactions. This study has identified new antigens based on trehalose esters of
synthetic MA that are promising candidates for diagnostic tests. They can be produced consis-
tently to a high purity in large quantities and thus have advantages over many other types of
antigen with diagnostic potential. We have shown that using them in combination (in a panel)
provides better diagnostic performance than using individual antigens, and that the results in
ELISA are dependent on the secondary antibody.
Numerous studies have described delay in the diagnosis and treatment of tuberculosis and
the key contribution of poor diagnostic capacity at the lower levels of the health services of dis-
ease-endemic areas where the majority of TB patients present [73]. The economic burden that
this delay places on people seeking diagnosis is enormous. A recent study reported that the
total costs of TB to patients in low and middle-income countries was equivalent, on average, to
39% of annual household income [74]. Half the total cost was incurred before treatment. New,
more accessible TB diagnostics are required that can bring diagnosis and prompt treatment to
the health centres where most patients initially present with their symptoms. Even if a simple,
rapid TB test could only diagnose patients with smear positive disease it could be a significant
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step forward in TB control. It would take TB diagnosis to settings where no sputum smear
microscopy currently exists or where smear microscopy labs are overburdened, under-
resourced or of poor quality.
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